MARKET

INVA

INVA

Innoviva
NASDAQ
21.63
-0.17
-0.78%
After Hours: 21.63 0 0.00% 16:49 02/09 EST
OPEN
21.88
PREV CLOSE
21.80
HIGH
21.93
LOW
21.26
VOLUME
691.06K
TURNOVER
--
52 WEEK HIGH
22.76
52 WEEK LOW
16.52
MARKET CAP
1.62B
P/E (TTM)
16.76
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INVA last week (0202-0206)?
Weekly Report · 12h ago
Weekly Report: what happened at INVA last week (0126-0130)?
Weekly Report · 02/02 10:27
Is It Time To Reassess Innoviva (INVA) After Strong Multi Year Share Price Gains
Simply Wall St · 01/28 18:37
Assessing Innoviva (INVA) Valuation After Recent Share Price Cooling
Simply Wall St · 01/27 14:25
Armata Pharmaceuticals Extends Loan Maturities With Innoviva to 2027
Reuters · 01/26 13:01
Weekly Report: what happened at INVA last week (0119-0123)?
Weekly Report · 01/26 10:27
MRNA is S&P 500’s top performing stock, here are the best Quant pharma companies
Seeking Alpha · 01/21 19:36
Weekly Report: what happened at INVA last week (0112-0116)?
Weekly Report · 01/19 10:34
More
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Webull offers Innoviva Inc stock information, including NASDAQ: INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.